E Fund CSI Medical Service ETF(159847) Rises 1.26% Intraday,Institutions Flag Rising Investment Heat in AI+Medical

NewTimeSpace News: As of 14:25 on April 10, 2026, the CSI Medical Index (399989) surged 1.33%. Constituent stocks: Andon Health rose 5.79%, Micro-Tech Endoscopy 4.49%, Tigermed 3.91%, followed by gains in Haoyuan Pharma, Joinn Laboratories and other stocks. E Fund CSI Medical Service ETF(159847) rose 1.26% to 0.4 yuan. Over the longer term, as of April 9, 2026, the ETF had climbed 5.60% cumulatively in the past two weeks, ranking 1/4 among comparable funds in return. (Stocks listed above are index constituents only, no specific recommendation implied.)

In terms of liquidity, E Fund CSI Medical Service ETFposted an intraday turnover rate of 0.92% and trading volume of 13.5410 million yuan. As of April 9, its average daily trading volume in the past year reached 19.1841 million yuan.

In terms of size, the ETF expanded by 37.9213 million yuan in the past two weeks, achieving notable growth, with new scale ranking 2/4 among comparable funds. (Data source: Wind)

In terms of shares, the ETF’s share count increased by 23 million units in the past week, showing strong growth, with new shares ranking 2/4 among comparable funds. (Data source: Wind)

In terms of capital flows, the ETF recorded a latest net capital outflow of 1.1907 million yuan. Over the past four trading days, there were three days of net inflows, totaling 26.6957 million yuan, with an average daily net inflow of 6.6739 million yuan. (Data source: Wind)

As of April 9, the ETF’s net value rose 9.74% over the past year, ranking first among comparable funds.

In terms of profitability, since inception as of April 9, 2026, the ETF had a maximum single-month return of 29.92%, a longest winning streak of 5 months with a cumulative gain of 24.30%, and an average return of 5.82% in rising months. It had outperformed its benchmark by an annualized return of 2.34% over the past year, ranking 1/4 among comparable funds.

In terms of drawdown, since the beginning of the year, the relative drawdown versus its benchmark was 0.04% as of April 9, the smallest among comparable funds.

In terms of fees, the management fee rate is 0.15% and the custody fee rate is 0.05%, the lowest among comparable funds.

In terms of tracking accuracy, as of April 9, 2026, the ETF’s tracking error over the past three years was 0.037%, the highest among comparable funds.

From a valuation perspective, the latest P/E ratio (TTM) of the CSI Medical Index tracked by E Fund CSI Medical Service ETFwas only 29.35 times, at the 8.43rd percentile of the past year, meaning its valuation was lower than 91.57% of the time in the past year and at a historical low level.

E Fund CSI Medical Service ETFclosely tracks the CSI Medical Index, which selects listed companies in the pharmaceutical and healthcare sector engaged in medical devices, medical services, medical informatization and other medical themes as index samples to reflect the overall performance of medical-themed listed securities.

Data showed that as of March 31, 2026, the top 10 weighted stocks of the CSI Medical Index (399989) were WuXi AppTec, Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, Pharmaron Beijing, Tigermed, Intco Medical, Andon Health, Asymchem Laboratories, and HTM Medical. The top 10 weighted stocks accounted for 51.41% in total. (Stocks listed above are index constituents only, no specific recommendation implied.)

Shanghai Science and Technology Innovation Bank stated that in terms of segmented sectors, domestic medical investment enthusiasm is rapidly shifting from "biomedicine" to "hardcore medical devices" and "AI+medical".

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.